Bristol-myers Squibb Compnay

Lexicon Pharmaceuticals, Inc.

Syngene International Limited

Vijay T Ahuja

Richard A Hartz

John E Macor

Joanne J Bronson

Carolyn Diane Dzierba

Gene Michael Dubowchik

Prasanna Sivaprakasam

Susheel Jethanand Nara

Vivekananda M Vrudhula

Ashvinikumar V Gavai

Guanglin Luo

Kenneth Gordon Carson

John S Tokarski

Steven P Seitz

Derek J Norris

Yulian Zhang

Yingzhi Bi

Michael Alan Green

Christine M Tarby

Giovanni Cianchetta

Ramkumar Rajamani

Bireshwar Dasgupta

Ling Chen

Maheswaran Sivasamban Karatholuvhu

Swanee E Jacutin-Porte

Matthias Broekema

S Roy Kimura

David Kimball

Soojin Kwon

Greg Zipp

Michael Wichroski

Mohini Rajasagi

Julian C Lo

Michael Green

The invention relates generally to compounds that are Mer-Ax1 inhibitors, pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.

Uracil derivatives as Mer-AXL inhibitors

The disclosure generally relates to compounds of formula (I), including their salts, as well as compositions and methods of using the compounds to treat disorders associated with GSK-3. 

GSK-3 inhibitors

The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds to treat disorders associated with GSK-3. 

The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.

Aryl lactam kinase inhibitors

The present disclosure is generally directed to compounds of formula (I) which can inhibit AAKI (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAKI. 

Quinoline-based kinase inhibitors

The disclosure provides compounds of formula (I), including their salts, as well as compositions and methods of using the compounds. The compounds are CRF receptor antagonists and may be useful for treating disorders associated with abnormal CRF levels or aberrant functioning of CRF receptors. 

Substituted carbamate derivatives as modulators of corticotropin-releasing factor receptor activity

The invention relates to the compound (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-(6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino)-5-oxo-4,5-dihydropyrazine-2-carbonitrile, pharmaceutical compositions of the compound, and methods of using the compound for the treatment of psychiatric disorders and neurological diseases including depression, anxiety related disorders, irritable bowel syndrome, addiction and negative aspects of drug and alcohol withdrawal, and other conditions associated with CRF.

Pyrazinone modulator of corticotropin-releasing factor receptor activity

The present disclosure is generally directed to compounds which can modulate G-protein coupled receptor 88, compositions comprising such compounds, and methods for modulating G-protein coupled receptor 88.

Modulators of G protein-coupled receptor 88

The invention relates to the compound (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-(6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino)-5-oxo-4,5-dihydropyrazine-2-carbonitrile, pharmaceutical compositions of the compound, and methods of using the compound for the treatment of psychiatric disorders and neurological diseases including depression, anxiety related disorders, irritable bowel syndrome, addiction and negative aspects of drug and alcohol withdrawal, and other conditions associated with CRF. 

[object Object]

Growing community of inventors

Princeton, NJ, United States of America

Vijay T Ahuja